JP2013516482A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516482A5
JP2013516482A5 JP2012548137A JP2012548137A JP2013516482A5 JP 2013516482 A5 JP2013516482 A5 JP 2013516482A5 JP 2012548137 A JP2012548137 A JP 2012548137A JP 2012548137 A JP2012548137 A JP 2012548137A JP 2013516482 A5 JP2013516482 A5 JP 2013516482A5
Authority
JP
Japan
Prior art keywords
composition
dexmedetomidine
pharmaceutically acceptable
pharmaceutical composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012548137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516482A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020462 external-priority patent/WO2011085162A2/en
Publication of JP2013516482A publication Critical patent/JP2013516482A/ja
Publication of JP2013516482A5 publication Critical patent/JP2013516482A5/ja
Pending legal-status Critical Current

Links

JP2012548137A 2010-01-08 2011-01-07 局所経皮用デクスメデトミジン組成物およびそれらの使用方法 Pending JP2013516482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29344010P 2010-01-08 2010-01-08
US61/293,440 2010-01-08
PCT/US2011/020462 WO2011085162A2 (en) 2010-01-08 2011-01-07 Topical transdermal dexmedetomidine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2013516482A JP2013516482A (ja) 2013-05-13
JP2013516482A5 true JP2013516482A5 (enExample) 2014-02-27

Family

ID=44306157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548137A Pending JP2013516482A (ja) 2010-01-08 2011-01-07 局所経皮用デクスメデトミジン組成物およびそれらの使用方法

Country Status (10)

Country Link
US (1) US20130072532A1 (enExample)
EP (1) EP2521544A4 (enExample)
JP (1) JP2013516482A (enExample)
CN (1) CN102753169A (enExample)
AU (1) AU2011204315A1 (enExample)
CA (1) CA2786598A1 (enExample)
MX (1) MX2012007933A (enExample)
NZ (2) NZ601195A (enExample)
RU (1) RU2012133969A (enExample)
WO (1) WO2011085162A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470516A (zh) 2011-12-11 2015-03-25 瑞克欧制药有限公司 鼻内右美托咪定组合物和其使用方法
AU2014262960A1 (en) * 2013-05-06 2015-11-26 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
WO2015054063A1 (en) * 2013-10-07 2015-04-16 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
TWI704933B (zh) * 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
KR20180095733A (ko) * 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
KR20210113439A (ko) * 2016-10-31 2021-09-15 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
CA3045043A1 (en) 2016-12-31 2018-07-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN107929234B (zh) * 2017-12-25 2021-07-23 温州医科大学附属第一医院 一种应用于烧伤创面修复的外用制剂膏体
CN115154440A (zh) 2018-06-27 2022-10-11 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN113577556A (zh) * 2021-08-01 2021-11-02 武汉左点科技有限公司 一种用于阴道康复治疗的生物反馈电刺激方法及装置
WO2024037545A1 (zh) * 2022-08-17 2024-02-22 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Similar Documents

Publication Publication Date Title
JP2013516482A5 (enExample)
RU2012133969A (ru) Локальные трансдермальные композиции дексмедетомидина и способы их применения
JP5902628B2 (ja) 相乗的抗ウイルス組成物及びその使用
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
JP2008044951A5 (enExample)
JP2015513309A5 (enExample)
JP2014515373A5 (enExample)
CN111565716B (zh) 使用地匹福林的方法
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
ES3029560T3 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
IL318427A (en) Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline
JP2012525358A5 (enExample)
JP2016505050A5 (enExample)
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
JP2019516797A5 (enExample)
JP6659819B2 (ja) 化学療法に関連する脱毛の軽減方法
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
CN115551515A (zh) 靶向3CLpro的连翘苷及其衍生物和抗新冠应用
CN102596194A (zh) 组合药物
JP7634002B2 (ja) 新規小児用配合剤
EP4364812A3 (en) Intranasal administration of ketamine to cluster headache patients
RU2012114097A (ru) Терапевтический агент против хронической боли
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
JP2006508993A5 (enExample)